More on UCBJY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $151.73 |
|
|||
| Open | $151.73 | ||||
| 52 Wk High | $46.25 | ||||
| 52 Wk Low | $32.74 | ||||
| Day High | $151.73 | ||||
| Day Low | $151.73 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 34 | ||||
- UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members
- BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data
- Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB
- Myasthenia Gravis Foundation of America Launches MGFA Food Support Program to Advance Nutrition Access and Health Equity for Individuals with Myasthenia Gravis
- UCB to acquire Neurona Therapeutics for up to $1.15 billion
- UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
- UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting
- UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting
- UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
- UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa
Entities mentioned with ucbjy
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Dividend | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Show More...
